<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550743</url>
  </required_header>
  <id_info>
    <org_study_id>BrUOG 302</org_study_id>
    <nct_id>NCT02550743</nct_id>
  </id_info>
  <brief_title>BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study</brief_title>
  <official_title>BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>howard safran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lifespan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals Corporation (Financial supporter)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this Brown University Oncology Research Group is to determine that a safe&#xD;
      dose of BYL719 can be administered with capecitabine and radiation in patients with rectal&#xD;
      cancer. Therefore, the threshold of success for this phase I study is to establish safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of accural&#xD;
  </why_stopped>
  <start_date type="Actual">June 3, 2016</start_date>
  <completion_date type="Actual">November 16, 2018</completion_date>
  <primary_completion_date type="Actual">November 16, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a phase I dose escalation study adding BYL719 to standard capecitabine and radiation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of BYL719</measure>
    <time_frame>approximately 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathologic Complete Response for Patients With Rectal Cancer</measure>
    <time_frame>Approximately 6-10 weeks post treatment</time_frame>
    <description>Pathologic complete response is defined as the lack of all signs of cancer in tissue samples removed during surgery or biopsy after treatment with radiation or chemotherapy.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYL719, capectabine and radiation Dose BYL719: 200mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYL719, capectabine and radiation Dose BYL719: 250mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYL719, capectabine and radiation Dose BYL719: 300mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BYL719, capectabine and radiation Dose BYL719: 150mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BYL719</intervention_name>
    <arm_group_label>Dose -1</arm_group_label>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Dose -1</arm_group_label>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <arm_group_label>Dose -1</arm_group_label>
    <arm_group_label>Dose 1</arm_group_label>
    <arm_group_label>Dose 2</arm_group_label>
    <arm_group_label>Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically proven adenocarcinoma of the rectum with no evidence&#xD;
             of distant metastases.&#xD;
&#xD;
          -  The tumor must be clinically Stage II (T3-4 N0) or stage III (N+). Stage of the tumor&#xD;
             may be determined by CT scan, endorectal ultrasound or MRI. (For patients receiving&#xD;
             chemotherapy prior to protocol chemoradiation, the initial clinical stage applies.&#xD;
             CT/MRI/PET should be performed within 2 months of study entry to exclude disease&#xD;
             progression.). For the MTD expansion phase only: patients who are stage IV, and in&#xD;
             whom it is planned to administer capecitabine and radiation then have a resection of&#xD;
             their rectal cancer, are also eligible.&#xD;
&#xD;
          -  Measurable disease not required at baseline. Patient's without measurable disease may&#xD;
             be enrolled as long as they clinically meet stage II or III criteria or for MTD&#xD;
             expansion phase: also stage IV.&#xD;
&#xD;
          -  Patients must not have received pelvic radiation for rectal cancer, or prior pelvic&#xD;
             radiation for any other malignancy that would prevent the patient from receiving the&#xD;
             required radiation treatments for this study. (Patients may receive neoadjuvant&#xD;
             chemotherapy prior to study chemoradiation)&#xD;
&#xD;
          -  Patients must not have an active concurrent invasive malignancy. Patients with prior&#xD;
             malignancies, including invasive colon cancer, are eligible if they are deemed by&#xD;
             their physician to be at low risk for recurrence. For example, patients with squamous&#xD;
             or basal cell carcinoma of the skin, melanoma in situ, carcinoma of the cervix, or&#xD;
             carcinoma in situ of the colon or rectum that have been effectively treated are&#xD;
             eligible, even if these conditions were diagnosed within 3 years prior to&#xD;
             registration.&#xD;
&#xD;
          -  Patients must be &gt; 18 years of age,&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Neutrophil Count &gt;1,000/µl, platelets &gt;100,000/µl, total bilirubin &lt; 1.5 x&lt; ULN ULN&#xD;
             (except for patients with Gilbert's syndrome who may only be included if total&#xD;
             bilirubin is &lt; 3xULN with direct bilirubin within normal range), ALT &lt;2.5xULN, AST &lt;&#xD;
             2.5xULN, creatinine &lt;1.5xULN, fasting plasma glucose &lt; 140 mg/dL and HbA1c &lt; 6.4%&#xD;
             (both criteria have to be met), anemia &gt; 9.0g/dL.Potassium, Calcium and Magnesium&#xD;
             (corrected for albumin) within normal range or &lt; grade 1 if determined not clinically&#xD;
             significant by treating investigator. INR &lt; 1.5&#xD;
&#xD;
          -  Patient is able to swallow and retain oral medication.&#xD;
&#xD;
          -  Left ventricular ejection fraction within normal &gt;50%&#xD;
&#xD;
          -  Signed informed consent and is able to comply with study and/or follow- up procedures.&#xD;
&#xD;
          -  QTcF &lt;480 msec&#xD;
&#xD;
          -  Patients history of diarrhea has been review and patient has been informed of&#xD;
             potential study drug induced diarrhea and management. This must be documented by&#xD;
             treating MD. See section 5 for baseline assessments of patient history of diarrhea.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has a known hypersensitivity to any of the excipients of BYL719 (alpelisib)&#xD;
&#xD;
          -  Suspected or confirmed metastatic disease including CNS involvement. For stage IV&#xD;
             patients: CNS involvement.&#xD;
&#xD;
          -  Patient with clinically manifest diabetes mellitus, or documented steroid induced&#xD;
             diabetes mellitus&#xD;
&#xD;
          -  Patient with impaired gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of oral BYL719 (e.g. ulcerative disease,&#xD;
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel&#xD;
             resection). Patients with colostomies are allowed unless colostomy is for one of the&#xD;
             precluded reason above.&#xD;
&#xD;
          -  Patient who has not recovered to grade 1 or better (except alopecia) from related side&#xD;
             effects of any prior antineoplastic therapy&#xD;
&#xD;
          -  Patient who has had systemic therapy within 4 weeks of starting study treatment (6&#xD;
             weeks for nitrosoureas or mitomycin C)&#xD;
&#xD;
          -  Patient who has undergone major surgery ≤ 4 weeks prior to starting study treatment or&#xD;
             in the investigators opinion who has not recovered from side effects of such procedure&#xD;
&#xD;
          -  Patient has any of the following cardiac abnormalities: A. symptomatic Congestive&#xD;
             heart failure i. history of documented congestive heart failure (New York Heart&#xD;
             Association functional classification III-IV), documented cardiomyopathy ii. Left&#xD;
             Ventricular Ejection Fraction (LVEF) &lt;50% as determined by Multiple Gated acquisition&#xD;
             (MUGA) scan or echocardiogram (ECHO) B. myocardial infarction &lt; 6 months prior to&#xD;
             enrollment C. unstable angina pectoris D. serious uncontrolled cardiac arrhythmia E.&#xD;
             symptomatic pericarditis F. QTcF &gt; 480 msec on the screening ECG (using the QTcF&#xD;
             formula)&#xD;
&#xD;
          -  Patient who is currently receiving medication with a known risk of prolonging the QT&#xD;
             interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be&#xD;
             discontinued or switched to a different medication prior to starting study drug&#xD;
             treatment. To be documented and submitted to BrUOG with registration. Please refer to&#xD;
             appendices F and G.&#xD;
&#xD;
          -  Patient who has participated in a prior investigational cancer treatment study within&#xD;
             30 days prior to enrollment. This refers to treatment not follow-up.&#xD;
&#xD;
          -  Patient is currently receiving warfarin or other coumarin derived anti-coagulant, for&#xD;
             treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight&#xD;
             heparin (LMWH), or fondaparinux is allowed. To be documented and submitted to BrUOG&#xD;
             with registration. Eliquis is allowed.&#xD;
&#xD;
          -  Patient is currently receiving treatment with drugs known to be strong inhibitors or&#xD;
             inducers of isoenzyme CYP3A. The patient must have discontinued strong inducers for at&#xD;
             least one week and must have discontinued strong inhibitors before the start of&#xD;
             treatment. Switching to a different medication prior to registration is allowed;&#xD;
             (Refer to Section Concomitant Medication, Appendix F and G).&#xD;
&#xD;
          -  Patient with known positive serology for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Patient with any other condition that would, in the Investigator's judgment, preclude&#xD;
             patient's participation in the clinical study due to safety concerns or compliance&#xD;
             with clinical study procedures, e.g. infection/inflammation, intestinal obstruction,&#xD;
             unable to swallow oral medication, social/psychological complications, chronic active&#xD;
             hepatitis, severe hepatic impairment etc&#xD;
&#xD;
          -  Patients who have other concurrent severe and/or uncontrolled medical conditions that&#xD;
             would, in the Treating Physician's judgment, contraindicate patient participation in&#xD;
             the individual patient program (eg. active or uncontrolled severe infection, chronic&#xD;
             active hepatitis, immuno-compromised, acute or chronic pancreatitis, uncontrolled high&#xD;
             blood pressure, interstitial lung disease, etc.)&#xD;
&#xD;
          -  Patient has a history of non-compliance to medical regimen or inability to grant&#xD;
             consent&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive hCG laboratory test (&gt; 5 mIU/mL). Pregnancy test not required for patients&#xD;
             who are considered post-menopausal and not of childbearing potential as defined below.&#xD;
&#xD;
        Women are considered post-menopausal and not of child-bearing potential if they have had 12&#xD;
        months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age&#xD;
        appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy&#xD;
        (with or without hysterectomy) at least six weeks ago.&#xD;
&#xD;
        For women with therapy-induced amenorrhea, oophorectomy or serial measurements of FSH&#xD;
        and/or estradiol are needed to ensure postmenopausal status.&#xD;
&#xD;
          -  Patient who does not apply highly effective contraception during the study and through&#xD;
             the duration as defined below after the final dose of study treatment:&#xD;
&#xD;
               1. Sexually active males (unless surgically sterilized at least 6 months prior to&#xD;
                  screening) should use a condom during intercourse while taking drug and for 6&#xD;
                  months after the final dose of study treatment and should not father a child in&#xD;
                  this period, but may be recommended to seek advice on conservation of sperm. The&#xD;
                  use of spermicidal foam is also highly suggested to be used with a condom as&#xD;
                  another form of protection. A condom is required to be used also by vasectomized&#xD;
                  men in order to prevent delivery of the drug via seminal fluid. Males should be&#xD;
                  cautioned to not donate sperm while actively receiving treatment on study.&#xD;
&#xD;
               2. Women of child-bearing potential, defined as all women physiologically capable of&#xD;
                  becoming pregnant, must use highly effective contraception during the study and&#xD;
                  through 6 months after the final dose of study treatment.&#xD;
&#xD;
          -  Herbal preparations/medications are not allowed throughout the study. These herbal&#xD;
             medications include, but are not limited to: St. John's wort, Kava, ephedra (ma&#xD;
             huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, Medical&#xD;
             Marijuana and ginseng. Patients need to stop using these herbal medications 7 days&#xD;
             prior to first dose of study drug.&#xD;
&#xD;
          -  Patient must not eat or drink Seville orange (and juice), grapefruit or grapefruit&#xD;
             juice, grapefruit hybrids, pummelos, starfruits and cranberry juice from 7 days prior&#xD;
             to the first dose of study drug and during the entire study treatment&#xD;
&#xD;
          -  Patient is currently receiving or has received systemic corticosteroids &lt; 2 weeks&#xD;
             prior to day 1 of study drug, or who has not fully recovered from side effects of&#xD;
             treatment. The following uses of corticosteroids are permitted: single doses, topical&#xD;
             applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways&#xD;
             diseases), eye drops or local injections (e.g., intra-articular).&#xD;
&#xD;
          -  Patient is concurrently using other anti-cancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Safran, MD</last_name>
    <role>Study Chair</role>
    <affiliation>BrUOG Study Chair</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rhode Island Hospital and The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <results_first_submitted>December 21, 2018</results_first_submitted>
  <results_first_submitted_qc>March 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 12, 2021</results_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>howard safran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stage II</keyword>
  <keyword>Stage III</keyword>
  <keyword>Stage IV</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT02550743/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dose 1</title>
          <description>BYL719, capectabine and radiation Dose: 200mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
        </group>
        <group group_id="P2">
          <title>Dose 2</title>
          <description>BYL719, capectabine and radiation Dose: 250mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
        </group>
        <group group_id="P3">
          <title>Dose 3</title>
          <description>BYL719, capectabine and radiation Dose: 300mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
        </group>
        <group group_id="P4">
          <title>Dose -1</title>
          <description>BYL719, capectabine and radiation Dose: 150mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>no patients were registered to dose level -1</population>
      <group_list>
        <group group_id="B1">
          <title>Dose 1</title>
          <description>BYL719, capectabine and radiation Dose: 200mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
        </group>
        <group group_id="B2">
          <title>Dose 2</title>
          <description>BYL719, capectabine and radiation Dose: 250mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
        </group>
        <group group_id="B3">
          <title>Dose 3</title>
          <description>BYL719, capectabine and radiation Dose: 300mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
        </group>
        <group group_id="B4">
          <title>Dose -1</title>
          <description>BYL719, capectabine and radiation Dose: 150mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="36" upper_limit="48"/>
                    <measurement group_id="B2" value="50" lower_limit="40" upper_limit="58"/>
                    <measurement group_id="B3" value="54" lower_limit="54" upper_limit="54"/>
                    <measurement group_id="B5" value="47.6" lower_limit="36" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unkown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose of BYL719</title>
        <time_frame>approximately 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maximum Tolerated Dose of BYL719</title>
            <description>BYL719, capectabine and radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose of BYL719</title>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">insufficient number of participants with events to determine MTD</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathologic Complete Response for Patients With Rectal Cancer</title>
        <description>Pathologic complete response is defined as the lack of all signs of cancer in tissue samples removed during surgery or biopsy after treatment with radiation or chemotherapy.</description>
        <time_frame>Approximately 6-10 weeks post treatment</time_frame>
        <population>No patients enrolled on dose -1.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose 1</title>
            <description>BYL719, capectabine and radiation Dose: 200mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
          </group>
          <group group_id="O2">
            <title>Dose 2</title>
            <description>BYL719, capectabine and radiation Dose: 250mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
          </group>
          <group group_id="O3">
            <title>Dose 3</title>
            <description>BYL719, capectabine and radiation Dose: 300mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
          </group>
          <group group_id="O4">
            <title>Dose -1</title>
            <description>BYL719, capectabine and radiation Dose: 150mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response for Patients With Rectal Cancer</title>
          <description>Pathologic complete response is defined as the lack of all signs of cancer in tissue samples removed during surgery or biopsy after treatment with radiation or chemotherapy.</description>
          <population>No patients enrolled on dose -1.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from time of consent through 30-days post treatment, an average of 3 months</time_frame>
      <desc>No patients were enrolled to dose -1.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose 1</title>
          <description>BYL719, capectabine and radiation Dose: 200mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
        </group>
        <group group_id="E2">
          <title>Dose 2</title>
          <description>BYL719, capectabine and radiation Dose: 250mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
        </group>
        <group group_id="E3">
          <title>Dose 3</title>
          <description>BYL719, capectabine and radiation Dose: 300mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
        </group>
        <group group_id="E4">
          <title>Dose -1</title>
          <description>BYL719, capectabine and radiation Dose: 150mg/day&#xD;
BYL719&#xD;
Capecitabine&#xD;
Radiation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic fistula</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>hypermagnesium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>watering eyes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>pain rectal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>vomit</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>pain perineal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>GI disorders other: rectal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>pelvic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>erythema multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>HTN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>pain abdominal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Dermatitis Radiation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>FPG-hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>pain vaginal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>vaginal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Safran, MD, Principal Investigator</name_or_title>
      <organization>Brown University Oncology Research Group (BrUOG)</organization>
      <phone>14018633000</phone>
      <email>kayla_rosati@brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

